Listed

Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Mar 31, 2016

Filed with the SEC on May 11, 2016 and accepted by EDGAR at May 11, 2016, 08:40 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2016-01-01 to 2016-03-31$4.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2016-01-01 to 2016-03-31−$15.6mus-gaap:OperatingIncomeLoss
Net income3 months2016-01-01 to 2016-03-31−$15.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-01-01 to 2016-03-31−$0.68us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-01-01 to 2016-03-31−$0.68us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-01-01 to 2016-03-3123,130,153 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2016-01-01 to 2016-03-31−$11.5mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash and equivalentsAt period end2016-03-31$134.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-03-31$135.6mus-gaap:AssetsCurrent
Total assetsAt period end2016-03-31$136.3mus-gaap:Assets
Current liabilitiesAt period end2016-03-31$11.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-03-31$14.6mus-gaap:Liabilities
Shareholders' equityAt period end2016-03-31$121.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-16-005855. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.